75 FR 180 pg. 56858 - Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Flunisolide, etc.); Correction
Type: RULEVolume: 75Number: 180Page: 56858
Docket number: [Docket No. FDA-2006-N-0304] (formerly Docket No. 2006N-0262)
FR document: [FR Doc. 2010-23195 Filed 9-16-10; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 2
[Docket No. FDA-2006-N-0304] (formerly Docket No. 2006N-0262)
RIN 0910-AF93
Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Flunisolide, etc.); Correction
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule; correction.
SUMMARY:
The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The document was published with an inadvertent error. This document corrects that error.
FOR FURTHER INFORMATION CONTACT:
Diane Sullivan, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171.
SUPPLEMENTARY INFORMATION:
In FR Doc. 2010-8467, appearing on page 19213, in the Federal Register of Wednesday, April 14, 2010, the following correction is made:
1. On page 19213, in the third column, the heading "RIN 0910-AF92" is corrected to read "RIN 0910-AF93".
Dated: September 13, 2010.
David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.
[FR Doc. 2010-23195 Filed 9-16-10; 8:45 am]
BILLING CODE 4160-01-S